Correlation Between Veracyte and Armata Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Veracyte and Armata Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Armata Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Veracyte and Armata Pharmaceuticals, you can compare the effects of market volatilities on Veracyte and Armata Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Armata Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Armata Pharmaceuticals.

Diversification Opportunities for Veracyte and Armata Pharmaceuticals

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between Veracyte and Armata is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Armata Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Armata Pharmaceuticals and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Armata Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Armata Pharmaceuticals has no effect on the direction of Veracyte i.e., Veracyte and Armata Pharmaceuticals go up and down completely randomly.

Pair Corralation between Veracyte and Armata Pharmaceuticals

Given the investment horizon of 90 days Veracyte is expected to generate 0.64 times more return on investment than Armata Pharmaceuticals. However, Veracyte is 1.55 times less risky than Armata Pharmaceuticals. It trades about 0.16 of its potential returns per unit of risk. Armata Pharmaceuticals is currently generating about -0.02 per unit of risk. If you would invest  3,029  in Veracyte on November 2, 2024 and sell it today you would earn a total of  1,585  from holding Veracyte or generate 52.33% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Veracyte  vs.  Armata Pharmaceuticals

 Performance 
       Timeline  
Veracyte 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.
Armata Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Armata Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest abnormal performance, the Stock's primary indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors.

Veracyte and Armata Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Veracyte and Armata Pharmaceuticals

The main advantage of trading using opposite Veracyte and Armata Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Armata Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will offset losses from the drop in Armata Pharmaceuticals' long position.
The idea behind Veracyte and Armata Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Complementary Tools

Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Transaction History
View history of all your transactions and understand their impact on performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency